1. Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. (15th July 2018) Authors: Warren, R.B.; Halliday, A.; Graham, C.N.; Gilloteau, I.; Miles, L.; McBride, D. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 12(2018) Page Start: 2178 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗